[HTML][HTML] Current Knowledge about CD3+CD20+ T Cells in Patients with Multiple Sclerosis
B Arneth - International Journal of Molecular Sciences, 2024 - mdpi.com
Multiple sclerosis (MS) is a disease of the central nervous system (CNS) characterized by
inflammation and autoimmune responses. This review explores the participation of T cells …
inflammation and autoimmune responses. This review explores the participation of T cells …
Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines
Y Yang, K Cheng, G Xu - European Journal of Pharmacology, 2024 - Elsevier
Primary membranous nephropathy (PMN) is an immune-mediated glomerular disease.
Rituximab (RTX) is recommended as a first-line immunosuppressive therapy and shows …
Rituximab (RTX) is recommended as a first-line immunosuppressive therapy and shows …
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study
AS Karl, R Klimas, M Katsimpoura, M Sgodzai… - Journal of …, 2024 - Springer
Abstract Introduction Ofatumumab (Kesimpta®) is a subcutaneous CD20-targeting antibody
approved in Germany in 2021 for the treatment of relapsing multiple sclerosis (RMS). After …
approved in Germany in 2021 for the treatment of relapsing multiple sclerosis (RMS). After …
Dental Adverse Effects of Anti-CD20 Therapies
H Bartak, T Fareh, N Ben Othman, D Viard… - Neurology and …, 2024 - Springer
Methods We reviewed 6 patient cases with dental disorders during anti-CD20 therapy that
were reported to the pharmacovigilance center. A disproportionality analysis was also …
were reported to the pharmacovigilance center. A disproportionality analysis was also …
Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder
D Stastna, M Vachova, P Dusek, G Fistravec… - Multiple Sclerosis and …, 2024 - Elsevier
Background AntiCD20 therapy, such as rituximab, ocrelizumab, or ofatumumab, effectively
treats patients with multiple sclerosis (pwMS) or neuromyelitis optica spectrum disorder …
treats patients with multiple sclerosis (pwMS) or neuromyelitis optica spectrum disorder …
Monoclonal Antibody Therapies in Cancer Immunotherapy
C Thanawiroon, B Yingngam - Critical Developments in Cancer …, 2024 - igi-global.com
Monoclonal antibodies (mAbs) can significantly improve patient outcomes in cancer
treatment while reducing related side effects, offering a targeted therapy alternative to …
treatment while reducing related side effects, offering a targeted therapy alternative to …
Monoclonal Antibody
B Yingngam - Critical Developments in Cancer Immunotherapy, 2024 - books.google.com
Monoclonal antibodies (mAbs) can significantly improve patient outcomes in cancer
treatment while reducing related side effects, offering a targeted therapy alternative to …
treatment while reducing related side effects, offering a targeted therapy alternative to …
Neue therapeutische Entwicklungen der Multiplen Sklerose
J Dann, A Haghikia, R Gold, S Faissner - Nervenheilkunde, 2024 - thieme-connect.com
Die Behandlungsmöglichkeiten der Multiplen Sklerose (MS) haben sich in den letzten 20
Jahren durch ein breites Arsenal von verlaufsmodifizierenden Immuntherapien massiv …
Jahren durch ein breites Arsenal von verlaufsmodifizierenden Immuntherapien massiv …
Estudio del índice kappa en las formas progresivas de esclerosis múltiple
S Fuentes Cantero - 2024 - idus.us.es
La esclerosis múltiple (EM) es una enfermedad inflamatoria, desmielinizante y
neurodegenerativa del sistema nervioso central. El curso clínico de la enfermedad se …
neurodegenerativa del sistema nervioso central. El curso clínico de la enfermedad se …
[PDF][PDF] Dental Adverse Effects of Anti-CD20 Therapies
HBTF Nouha, BOD Viard, MCFRE Ewig, MD Drici - 2024 - d-nb.info
Introduction: Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or
ofatumumab have seen an increase in interest in the treatment of neurological autoimmune …
ofatumumab have seen an increase in interest in the treatment of neurological autoimmune …